Zydus Lifesciences shares investor presentation for August 2026 roadshow

0 min read | Published on 17 Aug 2026, 04:56 PM |Updated on 23 Aug 2026, 12:39 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Zydus Lifesciences shares corporate presentation for investor meet
Investor roadshow scheduled for August 24-26, 2026
Event locations include Singapore and Hong Kong
Disclosure filed on August 23, following earlier notice

*this image is generated using AI for illustrative purposes only.

Zydus Lifesciences Limited has released its corporate presentation to be used during an investor meet scheduled from August 24 to 26, 2026. The company notified the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the disclosure on August 23, 2026.

This filing serves as a continuation of the company's earlier letter dated August 17, 2026, which announced a non-deal roadshow in Singapore and Hong Kong. Dhaval N. Soni, Company Secretary and Compliance Officer, signed the latest disclosure.

Event Details

The management team plans to meet with investors during the three-day period in late August to discuss the company's outlook and operations. The specific locations remain Singapore and Hong Kong.

Detail	Information
Event Type	Non-Deal Roadshow
Dates	August 24-26, 2026
Locations	Singapore, Hong Kong
Announced On	August 17, 2026
Presentation Filed On	August 23, 2026

Historical Stock Returns for Zydus Life Science

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.10%	-2.42%	+1.09%	+23.93%	+8.76%	+101.81%

How might investor sentiment from the Singapore and Hong Kong roadshows influence Zydus Lifesciences' stock valuation in the immediate quarter following August 2026?

What specific strategic initiatives or growth metrics is management likely to highlight to attract institutional interest in these key Asian financial hubs?

Could the focus on non-deal roadshows in Asia signal a shift in Zydus Lifesciences' capital raising strategy or international expansion plans for 2027?

Zydus Life Science

View Company Insights

View All News

Zydus Lifesciences receives independent ESG rating of 60 from ESGRAIL

0 min read | Published on 21 Aug 2026, 06:33 PM |Updated on 21 Aug 2026, 06:33 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Zydus Lifesciences received an independent ESG rating of 60 from ESGRAIL
The assessment was conducted without engagement from the company
Rating provider used publicly available information for the analysis
Disclosure made under Regulation 30 of SEBI Listing Regulations

*this image is generated using AI for illustrative purposes only.

Zydus Lifesciences Limited disclosed an independent environmental, social and governance (ESG) rating of 60 assigned by ESGRAIL on August 21, 2026.

The company confirmed that it did not engage the rating agency for this assessment. ESG Risk Assessments and Insights Limited (ESGRAIL), a SEBI-registered ESG Rating Provider, prepared the report independently using publicly available information.

Regulatory Disclosure

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also adheres to SEBI Circulars dated November 11, 2024, and December 31, 2024.

Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited, signed the filing submitted to both the BSE and NSE.

Historical Stock Returns for Zydus Life Science